Infanrix

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

6 competitors in Bradycardia

#DrugCompanyPhaseTrials

1

Atropen

FFresenius Kabi Taiwan Ltd.

Approved

32

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Approved

13

Robinul

Jazz Pharmaceuticals

Preclinical

24

Corlanor

Amgen

Preclinical

—5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

16

Infanrix

GSK

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity32 trials

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

Completed·GSK·Phase 2·NCT00627458·403 enrolled

Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

Completed·GSK·Phase 3·NCT00412854·660 enrolled

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

Completed·GSK·Phase 3·NCT00696423·467 enrolled

Show 29 more trials

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Completed·GSK·Phase 3·NCT02096263·585 enrolled

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Terminated·GSK·Phase 4·NCT00544271·720 enrolled

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

Completed·GSK·Phase 3·NCT00390910·286 enrolled

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Completed·GSK·Phase 2·NCT00513409·163 enrolled

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01341639·1,250 enrolled

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Completed·GSK·Phase 3·NCT00370396·1,200 enrolled

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Completed·Novartis·Phase 3·NCT00657709·3,630 enrolled

Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children

Not yet recruiting·GSK·Phase 2·NCT07320716·528 enrolled

Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

Completed·GSK·Phase 3·NCT00307034·351 enrolled

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Completed·GSK·Phase 3·NCT01353703·224 enrolled

To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines

Completed·GSK·Phase 3·NCT00366366·150 enrolled

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01480258·1,315 enrolled

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

Completed·GSK·Phase 2·NCT01204658·576 enrolled

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Completed·GSK·Phase 2·NCT01248884·721 enrolled

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

Completed·GSK·Phase 3·NCT01144663·2,095 enrolled

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Completed·GSK·Phase 3·NCT01086423·985 enrolled

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Completed·GSK·Phase 2·NCT01616459·953 enrolled

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Completed·GSK·Phase 2·NCT01453998·657 enrolled

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Completed·GSK·Phase 3·NCT01309646·454 enrolled

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Completed·GSK·Phase 3·NCT00327184·709 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Completed·GSK·Phase 2·NCT01171989·391 enrolled

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

Completed·GSK·Phase 4·NCT00753649·224 enrolled

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Completed·GSK·Phase 2·NCT00970307·421 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

Completed·Merck & Co.·Phase 3·NCT04031846·1,184 enrolled

Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age

Completed·GSK·Phase 2·NCT00376779·450 enrolled

Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

Completed·Merck & Co.·Phase 3·NCT00432042·955 enrolled

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Completed·GSK·Phase 3·NCT00586612·313 enrolled

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Completed·GSK·Phase 3·NCT01627561·148 enrolled

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Completed·GSK·Phase 3·NCT01000974·4,003 enrolled

Vaccine9 trials

Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.

Completed·GSK·Phase 2·NCT00729001·529 enrolled

Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine

Withdrawn·GSK·Phase 2·NCT01110044

Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

Completed·GSK·Phase 3·NCT00508261·793 enrolled

Show 6 more trials

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Completed·GSK·Phase 2·NCT01090453·480 enrolled

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Completed·GSK·Phase 2·NCT00129116·388 enrolled

Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib

Completed·GSK·Phase 3·NCT00652951·780 enrolled

Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™

Completed·Sanofi·Phase 3·NCT00654901·881 enrolled

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Terminated·GSK·Phase 2·NCT00871741·16 enrolled

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Completed·GSK·Phase 3·NCT00614614·1,558 enrolled

Vaccination5 trials

Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam

Completed·GSK·Phase 3·NCT01153841·300 enrolled

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment

Completed·GSK·Phase 4·NCT01235949·850 enrolled

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Completed·GSK·Phase 3·NCT00808444·466 enrolled

Show 2 more trials

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age

Completed·GSK·Phase 3·NCT00533507·230 enrolled

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age

Completed·GSK·Phase 3·NCT00489554·230 enrolled

Children4 trials

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Completed·GSK·Phase 3·NCT00463437·1,437 enrolled

Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00624819·524 enrolled

Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children

Completed·GSK·Phase 4·NCT00611559·283 enrolled

Show 1 more trial

Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia

Completed·GSK·Phase 4·NCT01094171·400 enrolled

Pregnancy3 trials

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

Completed·UUniversiteit Antwerpen·Phase 4·NCT02408926·370 enrolled

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Completed·GSK·Phase 4·NCT02422264·601 enrolled

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Completed·GSK·Phase 4·NCT02853929·551 enrolled

13 more indications

Treatment3 trials

Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines

Completed·GSK·Phase 3·NCT00370318·400 enrolled

Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa

Completed·Pfizer·Phase 4·NCT00294294·300 enrolled

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Completed·GSK·Phase 3·NCT00496015·750 enrolled

Vaccines2 trials

Duration of Protection: GSK DTaP Vaccines

Completed·GSK··NCT02447978·1 enrolled

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Completed·GSK·Phase 2·NCT00134719·1,104 enrolled

Bradycardia1 trial

DTaP and Apnea/Bradycardia in Preterm Infants

Completed·AAmerican SIDS Institute·N/A·NCT00482781·191 enrolled

ALS1 trial

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Completed·GSK·Phase 3·NCT00322335·230 enrolled

Medication1 trial

Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®

Completed·Pfizer·Phase 4·NCT01392378·908 enrolled

Hepatitis B1 trial

Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children

Completed·LLaval University·Phase 4·NCT04294433·431 enrolled

Acute otitis media1 trial

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00466947·23,802 enrolled

Antibody1 trial

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Completed·GSK·Phase 4·NCT00454987·288 enrolled

Influenza1 trial

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Completed·GSK·Phase 2·NCT00127855·409 enrolled

Diphtheria1 trial

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Completed·GSK·Phase 3·NCT00197236·468 enrolled

Immune Response1 trial

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Completed·GSK·Phase 3·NCT00148941·4,209 enrolled

Rotavirus Vaccine1 trial

Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants

Completed·GSK·Phase 3·NCT01171963·3,340 enrolled

Unspecified1 trial

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS

Recruiting·Pfizer·Phase 3·NCT07160244·6,000 enrolled

Details

Drug Info

Related News